<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 19:01:50 -0700</creation_date>
  <update_date>2013-04-11 14:04:57 -0600</update_date>
  <accession>HMDBP02040</accession>
  <secondary_accessions>
    <accession>7519</accession>
    <accession>HMDBP03927</accession>
  </secondary_accessions>
  <protein_type>Transporter</protein_type>
  <synonyms>
    <synonym>ATP-binding cassette sub-family C member 3</synonym>
    <synonym>MOAT-D</synonym>
    <synonym>Multi-specific organic anion transporter D</synonym>
    <synonym>Multidrug resistance-associated protein 3</synonym>
  </synonyms>
  <gene_name>ABCC3</gene_name>
  <general_function>Involved in ATP binding</general_function>
  <specific_function>May act as an inducible transporter in the biliary and intestinal excretion of organic anions. Acts as an alternative route for the export of bile acids and glucuronides from cholestatic hepatocytes</specific_function>
  <pathways>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB00036</accession>
      <name>Taurocholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00307</accession>
      <name>1b-Hydroxycholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00308</accession>
      <name>3b-Hydroxy-5-cholenoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00311</accession>
      <name>3b,4b,7a,12a-Tetrahydroxy-5b-cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00312</accession>
      <name>3a,7a,12b-Trihydroxy-5b-cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00316</accession>
      <name>2b,3a,7a,12a-Tetrahydroxy-5b-cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00320</accession>
      <name>3a,4b,7a-Trihydroxy-5b-cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00326</accession>
      <name>1b,3a,12a-Trihydroxy-5b-cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00328</accession>
      <name>12-Ketodeoxycholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00330</accession>
      <name>3a,4b,12a-Trihydroxy-5b-cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00340</accession>
      <name>3a,7a,12a,19-Tetrahydroxy-5b-cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00348</accession>
      <name>3b,12a-Dihydroxy-5a-cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00359</accession>
      <name>3a,7a-Dihydroxycoprostanic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00361</accession>
      <name>3b,7a-Dihydroxy-5b-cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00364</accession>
      <name>3a,6a,7b-Trihydroxy-5b-cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00367</accession>
      <name>3a,6b,7b,12a-Tetrahydroxy-5b-cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00371</accession>
      <name>1,3,12-Trihydroxycholan-24-oic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00376</accession>
      <name>3b,7a,12a-Trihydroxy-5a-Cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00377</accession>
      <name>3a,6b,7b,12b-Tetrahydroxy-5b-cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00381</accession>
      <name>Allolithocholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00384</accession>
      <name>3a,7a-Dihydroxycholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00385</accession>
      <name>12a-Hydroxy-3-oxocholadienic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00390</accession>
      <name>3a,7b,12b-Trihydroxy-5b-cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00391</accession>
      <name>7-Ketodeoxycholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00395</accession>
      <name>3b,7b,12a-Trihydroxy-5b-cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00399</accession>
      <name>3a,6b,7a,12a-Tetrahydroxy-5b-cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00400</accession>
      <name>3,7-Dihydroxy-12-oxocholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00404</accession>
      <name>2b,3a,7a-Trihydroxy-5b-cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00411</accession>
      <name>3a,12b-Dihydroxy-5b-cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00414</accession>
      <name>1b,3a,7a-Trihydroxy-5b-cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00415</accession>
      <name>3a,6b,7b-Trihydroxy-5b-cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00419</accession>
      <name>3b,7a,12a-Trihydroxy-5b-cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00427</accession>
      <name>3b,7b,12a-Trihydroxy-5a-Cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00432</accession>
      <name>3a,7b,12a-Trihydroxy-5a-Cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00433</accession>
      <name>1,3,7,12-Tetrahydroxycholan-24-oic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00437</accession>
      <name>3a,4b,7a,12a-Tetrahydroxy-5b-cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00438</accession>
      <name>3b,12a-Dihydroxy-5b-cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00447</accession>
      <name>7a,12a-Dihydroxy-3-oxo-4-cholenoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00460</accession>
      <name>7-Hydroxy-3-oxocholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00467</accession>
      <name>Nutriacholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00476</accession>
      <name>3-Oxo-4,6-choladienoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00478</accession>
      <name>Allodeoxycholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00502</accession>
      <name>3-Oxocholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00503</accession>
      <name>7a-Hydroxy-3-oxo-5b-cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00505</accession>
      <name>Allocholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00506</accession>
      <name>Alpha-Muricholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00514</accession>
      <name>Allochenodeoxycholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00518</accession>
      <name>Chenodeoxycholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00527</accession>
      <name>6a,12a-Dihydroxylithocholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00545</accession>
      <name>Chenodeoxycholic acid disulfate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00601</accession>
      <name>Coprocholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00619</accession>
      <name>Cholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00626</accession>
      <name>Deoxycholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00659</accession>
      <name>Deoxycholic acid disulfate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00664</accession>
      <name>Isohyodeoxycholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00686</accession>
      <name>Isoursodeoxycholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00713</accession>
      <name>Isoallolithocholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00717</accession>
      <name>Isolithocholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00733</accession>
      <name>Hyodeoxycholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00760</accession>
      <name>Hyocholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00761</accession>
      <name>Lithocholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00811</accession>
      <name>Murocholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00865</accession>
      <name>Muricholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00907</accession>
      <name>Sulfolithocholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00917</accession>
      <name>Ursocholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00946</accession>
      <name>Ursodeoxycholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01181</accession>
      <name>4a-Carboxy-4b-methyl-5a-cholesta-8,24-dien-3b-ol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02082</accession>
      <name>Bisnorcholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02163</accession>
      <name>Trihydroxycoprostanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02195</accession>
      <name>Varanic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02421</accession>
      <name>7-Sulfocholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02430</accession>
      <name>(3a,5b,7a)-23-Carboxy-7-hydroxy-24-norcholan-3-yl-b-D-Glucopyranosiduronic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02431</accession>
      <name>12b-Hydroxy-5b-cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02451</accession>
      <name>7b,12a-Dihydroxycholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02488</accession>
      <name>7a,12b-dihydroxy-5b-Cholan-24-oic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02492</accession>
      <name>7a-Hydroxy-5b-cholanic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02497</accession>
      <name>Glycochenodeoxycholate-3-sulfate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02504</accession>
      <name>3-Sulfodeoxycholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02522</accession>
      <name>Chenodeoxycholic acid sulfate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02536</accession>
      <name>Isodeoxycholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02585</accession>
      <name>3b,12b-Dihydroxy-5b-cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02586</accession>
      <name>Chenodeoxycholic acid 3-sulfate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02642</accession>
      <name>Ursodeoxycholic acid 3-sulfate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03873</accession>
      <name>3a,7a,12a-Trihydroxy-5b-cholestanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB06898</accession>
      <name>Chenodeoxyglycocholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00125</accession>
      <name>Glutathione</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00121</accession>
      <name>Folic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14010</accession>
      <name>5-Hydroxyomeprazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14656</accession>
      <name>Cisplatin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14681</accession>
      <name>Vincristine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14703</accession>
      <name>Methotrexate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01562</accession>
      <name>N5-Formyl-THF</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13961</accession>
      <name>O-Desmethylverapamil (D-702)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14911</accession>
      <name>Etoposide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15132</accession>
      <name>Doxorubicin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15146</accession>
      <name>Metyrapone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15151</accession>
      <name>Glyburide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15166</accession>
      <name>Probenecid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15179</accession>
      <name>Rifampin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15247</accession>
      <name>Nifedipine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15269</accession>
      <name>Sulfinpyrazone</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>nucleotide binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transmembrane transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>active transmembrane transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>primary active transmembrane transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>p-p-bond-hydrolysis-driven transmembrane transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>atpase activity, coupled to transmembrane movement of substances</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>catalytic activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>hydrolase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>hydrolase activity, acting on acid anhydrides</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>pyrophosphatase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>nucleoside-triphosphatase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>atpase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>nucleoside binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>purine nucleoside binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>adenyl nucleotide binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>adenyl ribonucleotide binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>atp binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>transmembrane transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>establishment of localization</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>cell part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>intrinsic to membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>integral to membrane</description>
      <go_id/>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Membrane</subcellular_location>
    <subcellular_location>Multi-pass membrane protein</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>Chromosome:1</chromosome_location>
    <locus>17q22</locus>
    <gene_sequence>&gt;4584 bp
ATGGACGCCCTGTGCGGTTCCGGGGAGCTCGGCTCCAAGTTCTGGGACTCCAACCTGTCT
GTGCACACAGAAAACCCGGACCTCACTCCCTGCTTCCAGAACTCCCTGCTGGCCTGGGTG
CCCTGCATCTACCTGTGGGTCGCCCTGCCCTGCTACTTGCTCTACCTGCGGCACCATTGT
CGTGGCTACATCATCCTCTCCCACCTGTCCAAGCTCAAGATGGTCCTGGGTGTCCTGCTG
TGGTGCGTCTCCTGGGCAGACCTTTTTTACTCCTTCCATGGCCTGGTCCATGGCCGGGCC
CCTGCCCCTGTTTTCTTTGTCACCCCCTTGGTGGTGGGGGTCACCATGCTGCTGGCCACC
CTGCTGATACAGTATGAGCGGCTGCAGGGCGTACAGTCTTCGGGGGTCCTCATTATCTTC
TGGTTCCTGTGTGTGGTCTGCGCCATCGTCCCATTCCGCTCCAAGATCCTTTTAGCCAAG
GCAGAGGGTGAGATCTCAGACCCCTTCCGCTTCACCACCTTCTACATCCACTTTGCCCTG
GTACTCTCTGCCCTCATCTTGGCCTGCTTCAGGGAGAAACCTCCATTTTTCTCCGCAAAG
AATGTCGACCCTAACCCCTACCCTGAGACCAGCGCTGGCTTTCTCTCCCGCCTGTTTTTC
TGGTGGTTCACAAAGATGGCCATCTATGGCTACCGGCATCCCCTGGAGGAGAAGGACCTC
TGGTCCCTAAAGGAAGAGGACAGATCCCAGATGGTGGTGCAGCAGCTGCTGGAGGCATGG
AGGAAGCAGGAAAAGCAGACGGCACGACACAAGGCTTCAGCAGCACCTGGGAAAAATGCC
TCCGGCGAGGACGAGGTGCTGCTGGGTGCCCGGCCCAGGCCCCGGAAGCCCTCCTTCCTG
AAGGCCCTGCTGGCCACCTTCGGCTCCAGCTTCCTCATCAGTGCCTGCTTCAAGCTTATC
CAGGACCTGCTCTCCTTCATCAATCCACAGCTGCTCAGCATCCTGATCAGGTTTATCTCC
AACCCCATGGCCCCCTCCTGGTGGGGCTTCCTGGTGGCTGGGCTGATGTTCCTGTGCTCC
ATGATGCAGTCGCTGATCTTACAACACTATTACCACTACATCTTTGTGACTGGGGTGAAG
TTTCGTACTGGGATCATGGGTGTCATCTACAGGAAGGCTCTGGTTATCACCAACTCAGTC
AAACGTGCGTCCACTGTGGGGGAAATTGTCAACCTCATGTCAGTGGATGCCCAGCGCTTC
ATGGACCTTGCCCCCTTCCTCAATCTGCTGTGGTCAGCACCCCTGCAGATCATCCTGGCG
ATCTACTTCCTCTGGCAGAACCTAGGTCCCTCTGTCCTGGCTGGAGTCGCTTTCATGGTC
TTGCTGATTCCACTCAACGGAGCTGTGGCCGTGAAGATGCGCGCCTTCCAGGTAAAGCAA
ATGAAATTGAAGGACTCGCGCATCAAGCTGATGAGTGAGATCCTGAACGGCATCAAGGTG
CTGAAGCTGTACGCCTGGGAGCCCAGCTTCCTGAAGCAGGTGGAGGGCATCAGGCAGGGT
GAGCTCCAGCTGCTGCGCACGGCGGCCTACCTCCACACCACAACCACCTTCACCTGGATG
TGCAGCCCCTTCCTGGTGACCCTGATCACCCTCTGGGTGTACGTGTACGTGGACCCAAAC
AATGTGCTGGACGCCGAGAAGGCCTATGTGTCTGTGTCCTTGTTTAATATCTTAAGACTT
CCCCTCAACATGCTGCCCCAGTTAATCAGCAACCTGACTCAGGCCAGTGTGTCTCTGAAA
CGGATCCAGCAATTCCTGAGCCAAGAGGAACTTGACCCCCAGAGTGTGGAAAGAAAGACC
ATCTCCCCAGGCTATGCCATCACCATACACAGTGGCACCTTCACCTGGGCCCAGGACCTG
CCCCCCACTCTGCACAGCCTAGACATCCAGGTCCCGAAAGGGGCACTGGTGGCCGTGGTG
GGGCCTGTGGGCTGTGGGAAGTCCTCCCTGGTGTCTGCCCTGCTGGGAGAGATGGAGAAG
CTAGAAGGCAAAGTGCACATGAAGGGCTCCGTGGCCTATGTGCCCCAGCAGGCATGGATC
CAGAACTGCACTCTTCAGGAAAACGTGCTTTTCGGCAAAGCCCTGAACCCCAAGCGCTAC
CAGCAGACTCTGGAGGCCTGTGCCTTGCTAGCTGACCTGGAGATGCTGCCTGGTGGGGAT
CAGACAGAGATTGGAGAGAAGGGCATTAACCTGTCTGGGGGCCAGCGGCAGCGGGTCAGT
CTGGCTCGAGCTGTTTACAGTGATGCCGATATTTTCTTGCTGGATGACCCACTGTCCGCG
GTGGACTCTCATGTGGCCAAGCACATCTTTGACCACGTCATCGGGCCAGAAGGCGTGCTG
GCAGGCAAGACGCGAGTGCTGGTGACGCACGGCATTAGCTTCCTGCCCCAGACAGACTTC
ATCATTGTGCTAGCTGATGGACAGGTGTCTGAGATGGGCCCGTACCCAGCCCTGCTGCAG
CGCAACGGCTCCTTTGCCAACTTTCTCTGCAACTATGCCCCCGATGAGGACCAAGGGCAC
CTGGAGGACAGCTGGACCGCGTTGGAAGGTGCAGAGGATAAGGAGGCACTGCTGATTGAA
GACACACTCAGCAACCACACGGATCTGACAGACAATGATCCAGTCACCTATGTGGTCCAG
AAGCAGTTTATGAGACAGCTGAGTGCCCTGTCCTCAGATGGGGAGGGACAGGGTCGGCCT
GTACCCCGGAGGCACCTGGGTCCATCAGAGAAGGTGCAGGTGACAGAGGCGAAGGCAGAT
GGGGCACTGACCCAGGAGGAGAAAGCAGCCATTGGCACTGTGGAGCTCAGTGTGTTCTGG
GATTATGCCAAGGCCGTGGGGCTCTGTACCACGCTGGCCATCTGTCTCCTGTATGTGGGT
CAAAGTGCGGCTGCCATTGGAGCCAATGTGTGGCTCAGTGCCTGGACAAATGATGCCATG
GCAGACAGTAGACAGAACAACACTTCCCTGAGGCTGGGCGTCTATGCTGCTTTAGGAATT
CTGCAAGGGTTCTTGGTGATGCTGGCAGCCATGGCCATGGCAGCGGGTGGCATCCAGGCT
GCCCGTGTGTTGCACCAGGCACTGCTGCACAACAAGATACGCTCGCCACAGTCCTTCTTT
GACACCACACCATCAGGCCGCATCCTGAACTGCTTCTCCAAGGACATCTATGTCGTTGAT
GAGGTTCTGGCCCCTGTCATCCTCATGCTGCTCAATTCCTTCTTCAACGCCATCTCCACT
CTTGTGGTCATCATGGCCAGCACGCCGCTCTTCACTGTGGTCATCCTGCCCCTGGCTGTG
CTCTACACCTTAGTGCAGCGCTTCTATGCAGCCACATCACGGCAACTGAAGCGGCTGGAA
TCAGTCAGCCGCTCACCTATCTACTCCCACTTTTCGGAGACAGTGACTGGTGCCAGTGTC
ATCCGGGCCTACAACCGCAGCCGGGATTTTGAGATCATCAGTGATACTAAGGTGGATGCC
AACCAGAGAAGCTGCTACCCCTACATCATCTCCAACCGGTGGCTGAGCATCGGAGTGGAG
TTCGTGGGGAACTGCGTGGTGCTCTTTGCTGCACTATTTGCCGTCATCGGGAGGAGCAGC
CTGAACCCGGGGCTGGTGGGCCTTTCTGTGTCCTACTCCTTGCAGGTGACATTTGCTCTG
AACTGGATGATACGAATGATGTCAGATTTGGAATCTAACATCGTGGCTGTGGAGAGGGTC
AAGGAGTACTCCAAGACAGAGACAGAGGCGCCCTGGGTGGTGGAAGGCAGCCGCCCTCCC
GAAGGTTGGCCCCCACGTGGGGAGGTGGAGTTCCGGAATTATTCTGTGCGCTACCGGCCG
GGCCTAGACCTGGTGCTGAGAGACCTGAGTCTGCATGTGCATGGTGGCGAGAAGGTGGGG
ATCGTGGGCCGCACTGGGGCTGGCAAGTCTTCCATGACCCTTTGCCTGTTCCGCATCCTG
GAGGCGGCAAAGGGTGAAATCCGCATTGATGGCCTCAATGTGGCAGACATCGGCCTCCAT
GACCTGCGCTCTCAGCTGACCATCATCCCGCAGGACCCCATCCTGTTCTCGGGGACCCTG
CGCATGAACCTGGACCCCTTCGGCAGCTACTCAGAGGAGGACATTTGGTGGGCTTTGGAG
CTGTCCCACCTGCACACGTTTGTGAGCTCCCAGCCGGCAGGCCTGGACTTCCAGTGCTCA
GAGGGCGGGGAGAATCTCAGCGTGGGCCAGAGGCAGCTCGTGTGCCTGGCCCGAGCCCTG
CTCCGCAAGAGCCGCATCCTGGTTTTAGACGAGGCCACAGCTGCCATCGACCTGGAGACT
GACAACCTCATCCAGGCTACCATCCGCACCCAGTTTGATACCTGCACTGTCCTGACCATC
GCACACCGGCTTAACACTATCATGGACTACACCAGGGTCCTGGTCCTGGACAAAGGAGTA
GTAGCTGAGTTTGATTCTCCAGCCAACCTCATTGCAGCTAGAGGCATCTTCTACGGGATG
GCCAGAGATGCTGGACTTGCCTAA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>1527</residue_number>
    <molecular_weight>169341.1</molecular_weight>
    <theoretical_pi>7.2</theoretical_pi>
    <pfams>
      <pfam>
        <name>ABC_membrane</name>
        <pfam_id>PF00664</pfam_id>
      </pfam>
      <pfam>
        <name>ABC_tran</name>
        <pfam_id>PF00005</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
      <region>33-53</region>
      <region>74-94</region>
      <region>100-120</region>
      <region>133-153</region>
      <region>172-192</region>
      <region>303-323</region>
      <region>350-370</region>
      <region>427-447</region>
      <region>451-471</region>
      <region>534-554</region>
      <region>577-597</region>
      <region>964-984</region>
      <region>1022-1042</region>
      <region>1086-1106</region>
      <region>1108-1128</region>
      <region>1200-1220</region>
      <region>1223-1243</region>
    </transmembrane_regions>
    <signal_regions>
      <region>None</region>
    </signal_regions>
    <protein_sequence>&gt;Canalicular multispecific organic anion transporter 2
MDALCGSGELGSKFWDSNLSVHTENPDLTPCFQNSLLAWVPCIYLWVALPCYLLYLRHHC
RGYIILSHLSKLKMVLGVLLWCVSWADLFYSFHGLVHGRAPAPVFFVTPLVVGVTMLLAT
LLIQYERLQGVQSSGVLIIFWFLCVVCAIVPFRSKILLAKAEGEISDPFRFTTFYIHFAL
VLSALILACFREKPPFFSAKNVDPNPYPETSAGFLSRLFFWWFTKMAIYGYRHPLEEKDL
WSLKEEDRSQMVVQQLLEAWRKQEKQTARHKASAAPGKNASGEDEVLLGARPRPRKPSFL
KALLATFGSSFLISACFKLIQDLLSFINPQLLSILIRFISNPMAPSWWGFLVAGLMFLCS
MMQSLILQHYYHYIFVTGVKFRTGIMGVIYRKALVITNSVKRASTVGEIVNLMSVDAQRF
MDLAPFLNLLWSAPLQIILAIYFLWQNLGPSVLAGVAFMVLLIPLNGAVAVKMRAFQVKQ
MKLKDSRIKLMSEILNGIKVLKLYAWEPSFLKQVEGIRQGELQLLRTAAYLHTTTTFTWM
CSPFLVTLITLWVYVYVDPNNVLDAEKAFVSVSLFNILRLPLNMLPQLISNLTQASVSLK
RIQQFLSQEELDPQSVERKTISPGYAITIHSGTFTWAQDLPPTLHSLDIQVPKGALVAVV
GPVGCGKSSLVSALLGEMEKLEGKVHMKGSVAYVPQQAWIQNCTLQENVLFGKALNPKRY
QQTLEACALLADLEMLPGGDQTEIGEKGINLSGGQRQRVSLARAVYSDADIFLLDDPLSA
VDSHVAKHIFDHVIGPEGVLAGKTRVLVTHGISFLPQTDFIIVLADGQVSEMGPYPALLQ
RNGSFANFLCNYAPDEDQGHLEDSWTALEGAEDKEALLIEDTLSNHTDLTDNDPVTYVVQ
KQFMRQLSALSSDGEGQGRPVPRRHLGPSEKVQVTEAKADGALTQEEKAAIGTVELSVFW
DYAKAVGLCTTLAICLLYVGQSAAAIGANVWLSAWTNDAMADSRQNNTSLRLGVYAALGI
LQGFLVMLAAMAMAAGGIQAARVLHQALLHNKIRSPQSFFDTTPSGRILNCFSKDIYVVD
EVLAPVILMLLNSFFNAISTLVVIMASTPLFTVVILPLAVLYTLVQRFYAATSRQLKRLE
SVSRSPIYSHFSETVTGASVIRAYNRSRDFEIISDTKVDANQRSCYPYIISNRWLSIGVE
FVGNCVVLFAALFAVIGRSSLNPGLVGLSVSYSLQVTFALNWMIRMMSDLESNIVAVERV
KEYSKTETEAPWVVEGSRPPEGWPPRGEVEFRNYSVRYRPGLDLVLRDLSLHVHGGEKVG
IVGRTGAGKSSMTLCLFRILEAAKGEIRIDGLNVADIGLHDLRSQLTIIPQDPILFSGTL
RMNLDPFGSYSEEDIWWALELSHLHTFVSSQPAGLDFQCSEGGENLSVGQRQLVCLARAL
LRKSRILVLDEATAAIDLETDNLIQATIRTQFDTCTVLTIAHRLNTIMDYTRVLVLDKGV
VAEFDSPANLIAARGIFYGMARDAGLA</protein_sequence>
  </protein_properties>
  <genbank_protein_id>3132270</genbank_protein_id>
  <uniprot_id>O15438</uniprot_id>
  <uniprot_name>MRP3_HUMAN</uniprot_name>
  <pdb_ids>
  </pdb_ids>
  <genbank_gene_id>AB010887</genbank_gene_id>
  <genecard_id>ABCC3</genecard_id>
  <geneatlas_id>ABCC3</geneatlas_id>
  <hgnc_id>HGNC:54</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Uchiumi T, Hinoshita E, Haga S, Nakamura T, Tanaka T, Toh S, Furukawa M, Kawabe T, Wada M, Kagotani K, Okumura K, Kohno K, Akiyama S, Kuwano M: Isolation of a novel human canalicular multispecific organic anion transporter, cMOAT2/MRP3, and its expression in cisplatin-resistant cancer cells with decreased ATP-dependent drug transport. Biochem Biophys Res Commun. 1998 Nov 9;252(1):103-10.</reference_text>
      <pubmed_id>9813153</pubmed_id>
    </reference>
    <reference>
      <reference_text>Kiuchi Y, Suzuki H, Hirohashi T, Tyson CA, Sugiyama Y: cDNA cloning and inducible expression of human multidrug resistance associated protein 3 (MRP3). FEBS Lett. 1998 Aug 14;433(1-2):149-52.</reference_text>
      <pubmed_id>9738950</pubmed_id>
    </reference>
    <reference>
      <reference_text>Belinsky MG, Bain LJ, Balsara BB, Testa JR, Kruh GD: Characterization of MOAT-C and MOAT-D, new members of the MRP/cMOAT subfamily of transporter proteins. J Natl Cancer Inst. 1998 Nov 18;90(22):1735-41.</reference_text>
      <pubmed_id>9827529</pubmed_id>
    </reference>
    <reference>
      <reference_text>Fromm MF, Leake B, Roden DM, Wilkinson GR, Kim RB: Human MRP3 transporter: identification of the 5'-flanking region, genomic organization and alternative splice variants. Biochim Biophys Acta. 1999 Jan 8;1415(2):369-74.</reference_text>
      <pubmed_id>9889399</pubmed_id>
    </reference>
    <reference>
      <reference_text>Konig J, Rost D, Cui Y, Keppler D: Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane. Hepatology. 1999 Apr;29(4):1156-63.</reference_text>
      <pubmed_id>10094960</pubmed_id>
    </reference>
    <reference>
      <reference_text>Zody MC, Garber M, Adams DJ, Sharpe T, Harrow J, Lupski JR, Nicholson C, Searle SM, Wilming L, Young SK, Abouelleil A, Allen NR, Bi W, Bloom T, Borowsky ML, Bugalter BE, Butler J, Chang JL, Chen CK, Cook A, Corum B, Cuomo CA, de Jong PJ, DeCaprio D, Dewar K, FitzGerald M, Gilbert J, Gibson R, Gnerre S, Goldstein S, Grafham DV, Grocock R, Hafez N, Hagopian DS, Hart E, Norman CH, Humphray S, Jaffe DB, Jones M, Kamal M, Khodiyar VK, LaButti K, Laird G, Lehoczky J, Liu X, Lokyitsang T, Loveland J, Lui A, Macdonald P, Major JE, Matthews L, Mauceli E, McCarroll SA, Mihalev AH, Mudge J, Nguyen C, Nicol R, O'Leary SB, Osoegawa K, Schwartz DC, Shaw-Smith C, Stankiewicz P, Steward C, Swarbreck D, Venkataraman V, Whittaker CA, Yang X, Zimmer AR, Bradley A, Hubbard T, Birren BW, Rogers J, Lander ES, Nusbaum C: DNA sequence of human chromosome 17 and analysis of rearrangement in the human lineage. Nature. 2006 Apr 20;440(7087):1045-9.</reference_text>
      <pubmed_id>16625196</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJ, Juijn JA, Baas F, Borst P: Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 1997 Aug 15;57(16):3537-47.</reference_text>
      <pubmed_id>9270026</pubmed_id>
    </reference>
    <reference>
      <reference_text>Hillman RT, Green RE, Brenner SE: An unappreciated role for RNA surveillance.  Genome Biol. 2004;5(2):R8. Epub 2004 Feb 2.</reference_text>
      <pubmed_id>14759258</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Taurocholic acid</name>
        <accession>HMDB00036</accession>
      </metabolite>
      <reference>
        <reference_text>Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD: Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32.</reference_text>
        <pubmed_id>11585759</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Taurocholic acid</name>
        <accession>HMDB00036</accession>
      </metabolite>
      <reference>
        <reference_text>Zelcer N, Saeki T, Bot I, Kuil A, Borst P: Transport of bile acids in multidrug-resistance-protein 3-overexpressing cells co-transfected with the ileal Na+-dependent bile-acid transporter. Biochem J. 2003 Jan 1;369(Pt 1):23-30.</reference_text>
        <pubmed_id>12220224</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Taurocholic acid</name>
        <accession>HMDB00036</accession>
      </metabolite>
      <reference>
        <reference_text>Zhang DW, Gu HM, Vasa M, Muredda M, Cole SP, Deeley RG: Characterization of the role of polar amino acid residues within predicted transmembrane helix 17 in determining the substrate specificity of multidrug resistance protein 3. Biochemistry. 2003 Aug 26;42(33):9989-10000.</reference_text>
        <pubmed_id>12924948</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Taurocholic acid</name>
        <accession>HMDB00036</accession>
      </metabolite>
      <reference>
        <reference_text>Hirohashi T, Suzuki H, Takikawa H, Sugiyama Y: ATP-dependent transport of bile salts by rat multidrug resistance-associated protein 3 (Mrp3). J Biol Chem. 2000 Jan 28;275(4):2905-10.</reference_text>
        <pubmed_id>10644759</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Taurocholic acid</name>
        <accession>HMDB00036</accession>
      </metabolite>
      <reference>
        <reference_text>Li T, Ito K, Horie T: Transport of fluorescein methotrexate by multidrug resistance-associated protein 3 in IEC-6 cells. Am J Physiol Gastrointest Liver Physiol. 2003 Sep;285(3):G602-10.</reference_text>
        <pubmed_id>12909565</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Taurocholic acid</name>
        <accession>HMDB00036</accession>
      </metabolite>
      <reference>
        <reference_text>Akita H, Suzuki H, Hirohashi T, Takikawa H, Sugiyama Y: Transport activity of human MRP3 expressed in Sf9 cells: comparative studies with rat MRP3. Pharm Res. 2002 Jan;19(1):34-41.</reference_text>
        <pubmed_id>11837698</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cholic acid</name>
        <accession>HMDB00619</accession>
      </metabolite>
      <reference>
        <reference_text>Hirohashi T, Suzuki H, Takikawa H, Sugiyama Y: ATP-dependent transport of bile salts by rat multidrug resistance-associated protein 3 (Mrp3). J Biol Chem. 2000 Jan 28;275(4):2905-10.</reference_text>
        <pubmed_id>10644759</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Glutathione</name>
        <accession>HMDB00125</accession>
      </metabolite>
      <reference>
        <reference_text>Zelcer N, Saeki T, Reid G, Beijnen JH, Borst P: Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem. 2001 Dec 7;276(49):46400-7.</reference_text>
        <pubmed_id>11581266</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Folic acid</name>
        <accession>HMDB00121</accession>
      </metabolite>
      <reference>
        <reference_text>Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD: Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32.</reference_text>
        <pubmed_id>11585759</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>5-Hydroxyomeprazole</name>
        <accession>HMDB14010</accession>
      </metabolite>
      <reference>
        <reference_text>Hitzl M, Klein K, Zanger UM, Fritz P, Nussler AK, Neuhaus P, Fromm MF: Influence of omeprazole on multidrug resistance protein 3 expression in human liver. J Pharmacol Exp Ther. 2003 Feb;304(2):524-30.</reference_text>
        <pubmed_id>12538803</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cisplatin</name>
        <accession>HMDB14656</accession>
      </metabolite>
      <reference>
        <reference_text>Schrenk D, Baus PR, Ermel N, Klein C, Vorderstemann B, Kauffmann HM: Up-regulation of transporters of the MRP family by drugs and toxins.  Toxicol Lett. 2001 Mar 31;120(1-3):51-7.</reference_text>
        <pubmed_id>11323161</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vincristine</name>
        <accession>HMDB14681</accession>
      </metabolite>
      <reference>
        <reference_text>Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD: Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32.</reference_text>
        <pubmed_id>11585759</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methotrexate</name>
        <accession>HMDB14703</accession>
      </metabolite>
      <reference>
        <reference_text>Akita H, Suzuki H, Hirohashi T, Takikawa H, Sugiyama Y: Transport activity of human MRP3 expressed in Sf9 cells: comparative studies with rat MRP3. Pharm Res. 2002 Jan;19(1):34-41.</reference_text>
        <pubmed_id>11837698</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methotrexate</name>
        <accession>HMDB14703</accession>
      </metabolite>
      <reference>
        <reference_text>Oleschuk CJ, Deeley RG, Cole SP: Substitution of Trp1242 of TM17 alters substrate specificity of human multidrug resistance protein 3. Am J Physiol Gastrointest Liver Physiol. 2003 Feb;284(2):G280-9. Epub 2002 Oct 9.</reference_text>
        <pubmed_id>12388190</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methotrexate</name>
        <accession>HMDB14703</accession>
      </metabolite>
      <reference>
        <reference_text>Hirohashi T, Suzuki H, Sugiyama Y: Characterization of the transport properties of cloned rat multidrug resistance-associated protein 3 (MRP3). J Biol Chem. 1999 May 21;274(21):15181-5.</reference_text>
        <pubmed_id>10329726</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methotrexate</name>
        <accession>HMDB14703</accession>
      </metabolite>
      <reference>
        <reference_text>Zeng H, Liu G, Rea PA, Kruh GD: Transport of amphipathic anions by human multidrug resistance protein 3.  Cancer Res. 2000 Sep 1;60(17):4779-84.</reference_text>
        <pubmed_id>10987286</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methotrexate</name>
        <accession>HMDB14703</accession>
      </metabolite>
      <reference>
        <reference_text>Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD: Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32.</reference_text>
        <pubmed_id>11585759</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methotrexate</name>
        <accession>HMDB14703</accession>
      </metabolite>
      <reference>
        <reference_text>Paumi CM, Wright M, Townsend AJ, Morrow CS: Multidrug resistance protein (MRP) 1 and MRP3 attenuate cytotoxic and transactivating effects of the cyclopentenone prostaglandin, 15-deoxy-Delta(12,14)prostaglandin J2 in MCF7 breast cancer cells. Biochemistry. 2003 May 13;42(18):5429-37.</reference_text>
        <pubmed_id>12731885</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methotrexate</name>
        <accession>HMDB14703</accession>
      </metabolite>
      <reference>
        <reference_text>Li T, Ito K, Horie T: Transport of fluorescein methotrexate by multidrug resistance-associated protein 3 in IEC-6 cells. Am J Physiol Gastrointest Liver Physiol. 2003 Sep;285(3):G602-10.</reference_text>
        <pubmed_id>12909565</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methotrexate</name>
        <accession>HMDB14703</accession>
      </metabolite>
      <reference>
        <reference_text>Zehnpfennig B, Urbatsch IL, Galla HJ: Functional reconstitution of human ABCC3 into proteoliposomes reveals a transport mechanism with positive cooperativity. Biochemistry. 2009 May 26;48(20):4423-30.</reference_text>
        <pubmed_id>19334674</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N5-Formyl-THF</name>
        <accession>HMDB01562</accession>
      </metabolite>
      <reference>
        <reference_text>Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD: Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32.</reference_text>
        <pubmed_id>11585759</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N5-Formyl-THF</name>
        <accession>HMDB01562</accession>
      </metabolite>
      <reference>
        <reference_text>Chen ZS, Robey RW, Belinsky MG, Shchaveleva I, Ren XQ, Sugimoto Y, Ross DD, Bates SE, Kruh GD: Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res. 2003 Jul 15;63(14):4048-54.</reference_text>
        <pubmed_id>12874005</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD: Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32.</reference_text>
        <pubmed_id>11585759</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Etoposide</name>
        <accession>HMDB14911</accession>
      </metabolite>
      <reference>
        <reference_text>Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD: Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32.</reference_text>
        <pubmed_id>11585759</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Etoposide</name>
        <accession>HMDB14911</accession>
      </metabolite>
      <reference>
        <reference_text>Zehnpfennig B, Urbatsch IL, Galla HJ: Functional reconstitution of human ABCC3 into proteoliposomes reveals a transport mechanism with positive cooperativity. Biochemistry. 2009 May 26;48(20):4423-30.</reference_text>
        <pubmed_id>19334674</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Etoposide</name>
        <accession>HMDB14911</accession>
      </metabolite>
      <reference>
        <reference_text>Zelcer N, Saeki T, Reid G, Beijnen JH, Borst P: Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem. 2001 Dec 7;276(49):46400-7.</reference_text>
        <pubmed_id>11581266</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxorubicin</name>
        <accession>HMDB15132</accession>
      </metabolite>
      <reference>
        <reference_text>Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD: Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32.</reference_text>
        <pubmed_id>11585759</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Metyrapone</name>
        <accession>HMDB15146</accession>
      </metabolite>
      <reference>
        <reference_text>Teng S, Jekerle V, Piquette-Miller M: Induction of ABCC3 (MRP3) by pregnane X receptor activators.  Drug Metab Dispos. 2003 Nov;31(11):1296-9.</reference_text>
        <pubmed_id>14570758</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Glyburide</name>
        <accession>HMDB15151</accession>
      </metabolite>
      <reference>
        <reference_text>Gedeon C, Behravan J, Koren G, Piquette-Miller M: Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. Placenta. 2006 Nov-Dec;27(11-12):1096-102. Epub 2006 Feb 3.</reference_text>
        <pubmed_id>16460798</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Probenecid</name>
        <accession>HMDB15166</accession>
      </metabolite>
      <reference>
        <reference_text>Zelcer N, Saeki T, Reid G, Beijnen JH, Borst P: Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem. 2001 Dec 7;276(49):46400-7.</reference_text>
        <pubmed_id>11581266</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Probenecid</name>
        <accession>HMDB15166</accession>
      </metabolite>
      <reference>
        <reference_text>Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD: Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32.</reference_text>
        <pubmed_id>11585759</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Probenecid</name>
        <accession>HMDB15166</accession>
      </metabolite>
      <reference>
        <reference_text>Zamek-Gliszczynski MJ, Xiong H, Patel NJ, Turncliff RZ, Pollack GM, Brouwer KL: Pharmacokinetics of 5 (and 6)-carboxy-2',7'-dichlorofluorescein and its diacetate promoiety in the liver. J Pharmacol Exp Ther. 2003 Feb;304(2):801-9.</reference_text>
        <pubmed_id>12538836</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rifampin</name>
        <accession>HMDB15179</accession>
      </metabolite>
      <reference>
        <reference_text>Teng S, Jekerle V, Piquette-Miller M: Induction of ABCC3 (MRP3) by pregnane X receptor activators.  Drug Metab Dispos. 2003 Nov;31(11):1296-9.</reference_text>
        <pubmed_id>14570758</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nifedipine</name>
        <accession>HMDB15247</accession>
      </metabolite>
      <reference>
        <reference_text>Teng S, Jekerle V, Piquette-Miller M: Induction of ABCC3 (MRP3) by pregnane X receptor activators.  Drug Metab Dispos. 2003 Nov;31(11):1296-9.</reference_text>
        <pubmed_id>14570758</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sulfinpyrazone</name>
        <accession>HMDB15269</accession>
      </metabolite>
      <reference>
        <reference_text>Zelcer N, Saeki T, Reid G, Beijnen JH, Borst P: Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem. 2001 Dec 7;276(49):46400-7.</reference_text>
        <pubmed_id>11581266</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
